Nomograms Based on Non-High-Density Lipoprotein to Predict Outcomes in Patients with Prior Coronary Artery Bypass Grafting with Acute Coronary Syndrome: A Single-Center Retrospective Study
Chuang Li,Kuizheng He,Yixing Yang,Kuibao Li,Mulei Chen,Lefeng Wang,Xiaorong Xu,Weiming Li
DOI: https://doi.org/10.2147/TCRM.S389694
2023-01-06
Therapeutics and Clinical Risk Management
Abstract:Chuang Li, &ast Kuizheng He, &ast Yixing Yang, Kuibao Li, Mulei Chen, Lefeng Wang, Xiaorong Xu, &ast Weiming Li &ast Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Weiming Li; Xiaorong Xu, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chao-Yang Hospital, Capital Medical University, 8&num Gong-Ti South Road, Beijing, 10020, People's Republic of China, Email ; Introduction: Non-high-density-lipoprotein cholesterol (non-HDL-C) is a secondary therapeutic target in cardiovascular diseases and is used for residual risk assessment in patients with coronary artery syndrome (ACS). This study was designed to determine the association between non-HDL-C in patients with prior coronary artery bypass graft (CABG) with ACS and clinical outcomes. Methods: We retrospectively analyzed 468 patients with prior CABG with ACS and categorized them into two groups based on the median non-HDL-C level. The primary endpoints were major adverse cardiovascular events (MACEs), including cardiovascular death and recurrent myocardial infarction. Kaplan–Meier curves, Cox proportional-hazard regressions, and restricted cubic splines were used to determine the association between non-HDL-C and MACEs. The discrimination and reclassification of the nomogram based on non-HDL-C were assessed using time-dependent receiver operating characteristic (ROC) curves and net reclassification improvement (NRI). Results: During the average follow-up time of 744.5 days, non-HDL-C was independently associated with the occurrence of MACEs (hazard ratio [HR] = 5.01, 95% confidence interval [CI] = 1.65– 15.24; p = 0.005) after adjusting for other lipid parameters. The spline curves indicated a linear relationship between non-HDL-C and MACEs (p-nonlinear: 0.863). The time-dependent areas under the ROC curves of prior-CABG-ACS nomograms containing non-HDL regarding MACEs in two consecutive years were 91.7 (95% CI: 85.5– 97.9) and 91.5 (95% CI: 87.3– 95.7), respectively. The NRI analysis indicated that the prior-CABG-ACS model improved the reclassification ability for 1- and 2-year MACEs (22.4% and 7%, p < 0.05, respectively). Discussion: Non-HDL is independently associated with the risk of MACEs in patients with prior CABG with ACS. The prior-CABG-ACS nomogram based on non-HDL-C and five convenient variables generates valid and stable predictions of MACE occurrence. Keywords: non-HDL cholesterol, major adverse cardiovascular events, prior coronary artery bypass grafting, GRACE score Patients with prior coronary artery bypass graft (CABG) account for 8–10% of individuals admitted for coronary artery syndrome (ACS). 1–3 Generally, patients with a history of CABG had a higher burden of cardiovascular (CV) risk factors, lower ejection fraction, and higher creatinine values on admission. This population is at a high risk of suffering from recurrent CV events in the short and long terms and requires personnel risk assessment to intensify medication therapy or implement intervention strategies to prevent the progression of atherosclerotic CV disease (ASCVD). Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor and the primary and secondary therapeutic target for ASCVD. In the context of mild-to-moderate hypertriglyceridemia and cardiometabolic disorders, such as diabetes mellitus, obesity, and metabolic syndrome, LDL-C levels underestimate the actual risk of ASCVD. 4,5 Non-high-density-lipoprotein cholesterol (non-HDL-C) is highly correlated with the concentrations of LDL-C and includes the atherogenic risk component of remnant lipoprotein particles. 6,7 Several lines of evidence suggest that non-HDL-C is superior to LDL-C for predicting residual ASCVD risk for statin-treated patients and has been identified as the secondary target in some treatment guidelines. 8–10 Non-HDL-C is more straightforward, convenient, and predictive than LDL-C; however, this test is not widely recognized and is less frequently used in clinical ASCVD assessments. 4 Few studies investigated the predictive value of non-HDL-C for CV outcomes in patients with prior CABG with ACS. Given these considerations, this study was designed to determine the ability of non-HDL-C to predict outcomes in patients with previous CABG with ACS undergoing percutaneous coronary intervention (PCI). Furthermore, we generated a nomogram to stratify this population's risk of CV events. Among the 14,288 patients with ACS undergoing PCI at Beijing Chaoyang Hospital Heart Center between -Abstract Truncated-
health care sciences & services